← Back to Search

Other

14C RPT193 400 mg for Healthy Male Subjects

Phase 1

Waitlist Available

Research Sponsored by RAPT Therapeutics, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 14 days

Awards & highlights

Study Summary

This trial studies how a medicine enters and leaves the body and how much of it is used.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 14 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~14 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and 14 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Characterize pharmacokinetics (PK) profile of RPT193

Quantitate total radioactivity (TRA)

Route(s) of elimination 1

+1 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: 14C RPT193 400 mgExperimental Treatment1 Intervention

Radiolabelled RPT193

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

14C RPT193

2023

Completed Phase 1

~10

Do I qualify?Apply below to find out

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

RAPT Therapeutics, Inc.Lead Sponsor

6 Previous Clinical Trials

851 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this experimental trial accept participants aged 50 and above?

"This research initiative is open to those individuals aged 19 and under 55."

Answered by AI

Is it possible for me to sign up as a participant in this clinical trial?

"Candidates that meet the criteria of being male, between 19 and 55 years old, with no major medical conditions are invited to join this trial. At present there is space for seven participants."

Answered by AI

Is the administration of 14C RPT193 400 mg a secure medical procedure for patients?

"Our team has evaluated 14C RPT193 400 mg as having a low level of safety due to its Phase 1 status, meaning there is only scarce evidence for both efficacy and safety."

Answered by AI

Are there any available vacancies for participants in this experiment?

"Per the data on clinicaltrials.gov, this particular medical trial is not currently recruiting patients. With an initial posting date of October 1st 2023 and its last update occuring on October 13th 2023, there are presently no enrolment opportunities for potential participants. However, 6 other trials are actively enrolling at present."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study of RPT193 in Healthy Adult Male Subjects

2023. "Study of RPT193 in Healthy Adult Male Subjects". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06087978.

All > Omaha